Core Insights - CLEAR has entered into a contract with the Centers for Medicare & Medicaid Services (CMS) to modernize identity verification for Medicare beneficiaries and providers on Medicare.gov, integrating CLEAR1 for account creation and recovery in early 2026 [1][3] Group 1: Identity Verification and Fraud Prevention - CLEAR1 addresses identity risk challenges in healthcare, reducing identity-related fraud and misuse of sensitive data through multi-layered verification [2] - The integration of CLEAR1 aims to enhance fraud prevention and restore trust in digital access to healthcare [2][4] Group 2: Support for CMS Initiatives - The partnership aligns with CMS' Health Tech Ecosystem initiative, which seeks to create a more connected and interoperable healthcare system [3] - CLEAR1's implementation is expected to reduce barriers to care and improve access for millions of Americans [4][5] Group 3: Compliance and Operational Efficiency - CLEAR1 is HIPAA-compliant and certified by Kantara Initiative for NIST IAL2/AAL2, reinforcing its role as a trusted identity solution in healthcare [4] - High-assurance digital identity solutions like CLEAR1 can enhance operational efficiency and reduce identity-related support volume [4] Group 4: Partnerships and Expansion - CLEAR has established partnerships with various health systems, including Epic, Sharecare, and Wellstar Health, to expand its footprint in the healthcare industry [5] - The growing network of partners indicates a commitment to delivering a secure and patient-centered healthcare system [5][6]

Core Viewpoint - NeuroPace, Inc. has responded positively to the Centers for Medicare & Medicaid Services (CMS) decision not to finalize the proposed reassignment of epilepsy neurostimulator cases in the FY 2026 Inpatient Prospective Payment System (IPPS) rule, maintaining the current reimbursement structure for its RNS System procedures [1][2]. Company Overview - NeuroPace, Inc. is a medical technology company based in Mountain View, California, focused on improving the lives of individuals with epilepsy by reducing or eliminating seizures through its innovative RNS System [3]. - The RNS System is the first and only commercially available brain-responsive platform that provides personalized, real-time treatment at the source of seizures, aiming to enhance care for patients with drug-resistant epilepsy and potentially benefiting those with other brain disorders [3]. Regulatory Engagement - The company appreciates CMS's willingness to consider public comments and its decision to retain the existing MS-DRG assignment for RNS System procedures, which supports hospitals serving Medicare beneficiaries with epilepsy [2]. - NeuroPace plans to continue collaborating with CMS on improvements related to MS-DRG and reimbursement policies to ensure access to the RNS System for all eligible patients [2].

Core Viewpoint - Organogenesis Holdings Inc. supports the Centers for Medicare & Medicaid Services' (CMS) proposed new payment methodology for skin substitutes, emphasizing the need for payment rates to reflect clinical value and relative cost [1][2]. Company Overview - Organogenesis Holdings Inc. is a leading regenerative medicine company focused on developing, manufacturing, and commercializing solutions for advanced wound care and surgical and sports medicine markets [3][5]. - The company offers a comprehensive portfolio of innovative regenerative products to meet patient needs across the continuum of care [3][5]. Industry Context - The proposed payment structure by CMS aims to establish a per centimeter square payment methodology based on FDA classification for skin substitutes, which is expected to reduce Medicare spending and ensure consistent payment across care settings [2]. - The new payment approach is anticipated to enhance access to innovative wound healing technologies, which have been shown to reduce life-threatening amputations and complications [2]. Future Outlook - With over forty years of leadership in regenerative medicine, the company is well-positioned for growth in the evolving wound care market [2]. - The company remains committed to collaborating with CMS and other stakeholders to refine proposed policies that promote long-term stability and expand access to PMA products [2].

Core Insights - Noridian Healthcare Solutions has been re-awarded the Durable Medical Equipment, Prosthetics, Orthotics and Supplies (DME) Medicare Jurisdiction A (JA) contract valued at $142 million by the Centers for Medicare & Medicaid Services (CMS) [1][3] Company Overview - Noridian has been serving the suppliers and beneficiaries of JA since 2015, demonstrating exceptional performance and commitment to reducing administrative barriers in healthcare access [3] - The company processes claims for Medicare beneficiaries in the District of Columbia and 11 states, including Connecticut, Delaware, Maine, Maryland, Massachusetts, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, and Vermont [2] Operational Performance - Noridian's DME team has achieved a 99% timely processing rate for Medicare claims, ensuring that healthcare suppliers and patients do not experience delays in funding [5] - The contract includes a base year and the option for six one-year extensions, with support staff located in Fargo and across the states within the JA jurisdiction [5] Service Scope - Noridian's responsibilities include claims processing, payment services, education and outreach, appeals, and addressing complex inquiries from beneficiaries and Congressional Offices [4] - The company manages over 20,000 DME suppliers and processes more than 11 million claims annually for Medicare beneficiaries in the JA region [4] Company Background - Noridian Healthcare Solutions develops solutions for federal, state, and commercial healthcare programs, offering a range of services including claims processing and medical review [6] - The company is headquartered in Fargo, ND, and operates nationwide, focusing on customizable, high-quality solutions to improve healthcare access [6]